Blog
RSS FeedPosted by Michael Wonder on 17 Aug 2023
Do France, Germany, and Italy agree on the added therapeutic value of medicines?
17 August 2023 - The Health Technology Assessment of medicines is performed separately at the country level with some differences, but ...
Posted by Michael Wonder on 13 Apr 2022
Europe’s new HTA system spurs more debate, concern
12 April 2022 - Fresh round of discussions around health technology assessment. ...
Posted by Michael Wonder on 13 Apr 2021
Europe tries to lower drug prices with small doses of transparency
13 April 2021 - For countries in Europe, negotiating a deal with a pharma company over drug prices is the ...
Posted by Michael Wonder on 22 Apr 2020
Managed Entry Agreements: policy analysis from the European perspective
21 April 2020 - This article begins with a short review of the existing taxonomy of managed entry agreements and includes ...
Posted by Michael Wonder on 15 May 2017
European Commission opens formal investigation into Aspen Pharma's pricing practices for cancer medicines
15 May 2017 - The European Commission has opened a formal investigation into concerns that Aspen Pharma has engaged in ...
Posted by Michael Wonder on 19 Nov 2016
The value of medicines: a crucial but vague concept
20 November 2016 - Health technology assessment is increasingly used to evaluate the value of health care products and to prioritise ...